Locations:
Search
Two thirds of patients responded to CAR T-cell therapy
On-demand stem cell mobilizer is an effective salvage strategy
Dispelling myths and sharing practical experiences
Research indicates strong rationale for expanding trial eligibility criteria
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Retrospective study yields clues to understanding risk of secondary myeloid neoplasms
Novel three-drug regimen used to manage life-threatening developments
Momelotinib, a new JAK inhibitor, inches closer to market approval
Claims data reveal disorder is often overlooked and undertreated
Management options expand in both inpatient and outpatient settings
Sudden-onset abdominal pain prompts urgent visit
Advertisement
Advertisement